Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) EBITDA Margin (2024 - 2025)

Kairos Pharma's EBITDA Margin history spans 2 years, with the latest figure at 2.91% for Q2 2025.

  • For Q2 2025, EBITDA Margin fell 185291.0% year-over-year to 2.91%; the TTM value through Jun 2025 reached 3.04%, changed N/A, while the annual FY2025 figure was 11.14%, 880.0% down from the prior year.
  • EBITDA Margin reached 2.91% in Q2 2025 per KAPA's latest filing, down from 2.53% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1850.0% in Q2 2024 to a low of 2.91% in Q2 2025.